Drug intelligence / Profile preview

PKM-02

Development stage: Preclinical
Lead developer: PKMed
Modality: Cell Therapies
Administration: Local Injection

Overview

PKM-02 is a preclinical **local injection** candidate from **PKMed** that uses a proprietary **cell homing technology** intended to enhance **hematopoietic stem cell engraftment** and improve outcomes of **allogeneic hematopoietic stem cell transplantation**. The program is being positioned for **hemoglobinopathies** and other **hematologic disorders eligible for allogeneic HSCT**. Publicly available PKMed pipeline information does not disclose a specific molecular target, named active substance, or detailed composition, so the asset is best characterized as an early-stage, platform-derived stem cell engraftment enhancement therapy rather than a fully chemically defined drug entity.

Other names: PKM-02PKM02PKM 02PKMed cell homing technology

Beyond the preview

Go deeper on PKM-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PKM-02.

Explore the full profile